17-May-2024
GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers
Seeking Alpha News (Thu, 16-May 10:00 AM ET)
TipRanks (Thu, 16-May 9:10 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), Moderna (MRNA)
TipRanks (Thu, 16-May 8:02 AM ET)
Celcuity’s Clinical and Financial Momentum Justifies Buy Rating and $24 Price Target
TipRanks (Thu, 16-May 6:26 AM ET)
Growth Potential Drives Buy Rating for Celcuity Despite Current Losses
TipRanks (Thu, 16-May 6:18 AM ET)
TipRanks (Wed, 15-May 8:12 PM ET)
Celcuity Non-GAAP EPS of -$0.59
Seeking Alpha News (Wed, 15-May 4:06 PM ET)
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
Globe Newswire (Wed, 15-May 4:01 PM ET)
Celcuity Shareholders Approve Stock Plan Expansion and Elect Board
TipRanks (Mon, 13-May 5:12 PM ET)
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
Globe Newswire (Wed, 8-May 7:05 AM ET)
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of May 17, 2024, CELC stock price declined to $16.76 with 227,294 million shares trading.
CELC has a beta of 1.09, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.07 to the broad based SPY ETF.
CELC has a market cap of $422.98 million. This is considered a Small Cap stock.
In the last 3 years, CELC stock traded as high as $33.01 and as low as $4.81.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, IWM, DWAS, VXF, IWN.
CELC has outperformed the market in the last year with a return of +67.2%, while the SPY ETF gained +29.1%. In the last 3 month period, CELC beat the market returning +10.0%, while SPY returned +6.3%. However, in the most recent 2 weeks CELC has underperformed the stock market by returning -5.1%, while SPY returned +3.6%.
CELC support price is $16.84 and resistance is $18.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC stock will trade within this expected range on the day.